ABEO Abeona Therapeutics Inc.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Abeona Therapeutics Inc., and Encourages Investors with Losses to Contact the Firm

Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Abeona Therapeutics Inc. (“Abeona” or the “Company”) (NASDAQ: ABEO). Investors who purchased or otherwise acquired Abeona Therapeutics Inc. shares between March 31, 2015 and June 19, 2015; and/or Abeona shares between June 22, 2015 and December 9, 2016 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the February 14, 2017 lead plaintiff motion deadline.

If you purchased shares of Abeona during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at [email protected].

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

Mako Research published a report on SeekingAlpha.com stating, "ABEO science is demonstrably unviable with numerous irrefutable flaws that will lead to failure." The report found that Steven H. Rouhandeh, the Company's Executive Chairman and Principal Executive Officer, was once the managing director at D. Blech & Co., a brokerage firm that was the subject of SEC investigations during the 1990s, as well as a securities class action suit that ended in a $15 million investor settlement because of claims that the firm changed the price of some biotech stocks through transactions that falsely inflated the market price of the stocks.

When this information was released to the investing public, the value of Abeona fell sharply, causing investors harm.

If you wish to learn more about this lawsuit at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].

This press release may constitute Attorney Advertising in some jurisdictions.

EN
25/01/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abeona Therapeutics Inc.

 PRESS RELEASE

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief...

Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the Company’s corporate strategy and business development functions, as well as drive operating efficiency for the Company. “Mohamad brings a wealth of experience in strategic planning and business development,” said Vish Seshadri, Chief Executive Officer of Abeo...

 PRESS RELEASE

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVA...

Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN, a first-of-its-kind, FDA-approved autologous, gene therapy is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa...

 PRESS RELEASE

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® ...

Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). ZEVASKYN was administered at Lucile Packard Children’s Hospital Stanford in Palo Alto, CA. “Treating our first patient is a proud moment for Abeona and a testament ...

 PRESS RELEASE

Abeona Therapeutics® Announces New Employee Inducement Grants Under Na...

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CLEVELAND, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On November 30, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to, in...

 PRESS RELEASE

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and ...

Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates - First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with broad market access provide foundation for sustainable commercial success - - $207.5M in cash, cash equivalents, restricted cash and short-term investments as of September 30, 2025 expected to fund operations for over two years - CLEVELAND, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch